Menu
The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract pharmacy restrictions as part of an ongoing congressional probe of the drug pricing program.

Latest Cassidy Probe Adds to Growing Scrutiny of 340B Contract Pharmacies, TPAs

William Newton, Associate Editor/Senior Writer 340B Report Views
An influential senator’s inquiry into the nation’s two largest 340B pharmacy chains comes amid growing scrutiny into 340B contract pharmacies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

AbbVie Pushes to Block Louisiana 340B Contract Law, New State AG Takes Office

$7.8 Billion in Refunds from Underpayments to 340B Hospitals Begin to Roll In

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live